Frontotemporal dementia

BMJ (Online)

Volumn 347, Issue 7920, 2013, Pages

  Warren, Jason D ^a   Rohrer, Jonathan D ^a   Rossor, Martin N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; FUSED IN SARCOMA PROTEIN; MEMANTINE; NEUROLEPTIC AGENT; OXYTOCIN; PAROXETINE; PROGRANULIN; SEROTONIN UPTAKE INHIBITOR; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRAZODONE;

ALZHEIMER DISEASE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPULSION; COUNSELING; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; HUMAN; LOGOPENIC APHASIA; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE NONFLUENT APHASIA; REVIEW; SEMANTIC DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPEECH THERAPY; SYMPTOM; DISEASE MANAGEMENT; PATHOLOGY; PSYCHOLOGICAL ASPECT;

DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; FRONTOTEMPORAL DEMENTIA; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84882420755     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4827     Document Type: Review

References (34)

1. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010;24:375-98.
2. Mackenzie IR, Neumann M, Baborie A. A harmonized classification system for FTD-TDP pathology. Acta Neuropathol 2011;122:111-3.
3. Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73:1451-6.
4. Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 2011;24:542-9.
5. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-77.
6. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-14.
7. Kipps CM, Hodges JR, Fryer TD, Nestor PJ. Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain 2009;132:2566-78.
8. Perry RJ, Graham A, Williams G, Rosen H, Erzinçlioglu S, Weiner M, et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord 2006;22:278-87. (Pubitemid 44651440)
9. Mendez MF, Shapira JS, McMurtray A, Licht E, Miller BL. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol 2007;64:830-5. (Pubitemid 46919837)
10. Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol 2007;6:1004-14. (Pubitemid 47562322)
11. Rohrer JD, Warren JD, Modat M, Ridgway GR, Douiri A, Rossor MN, et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009;72:1562-9.
12. Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, et al. The natural history of temporal variant frontotemporal dementia. Neurology 2005;64:1384-90. (Pubitemid 40570506)
13. Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: a clinical and neurolinguistic analysis. Neurology 2010;75:603-10.
14. Rohrer JD, Ridgway GR, Crutch SJ, Hailstone J, Goll JC, Clarkson MJ, et al. Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010;49:984-93.
15. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86.
16. Kertesz A, McMonagle P. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci 2010;15:138-43.
17. Xiong L, Xuereb JH, Spillantini MG, Patterson K, Hodges JR, Nestor PJ. Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology. J Neurol Neurosurg Psychiatry 2011;82:254-60.
18. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827-35. (Pubitemid 351653951)
19. Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, et al. Additional value of CSF amyloid beta 40 levels in the differentiation between FTD and control subjects. J Alzheimers Dis 2010;20:445-52.
20. McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van Deerlin VM, et al. Can MRI screen for CSF biomarkers in neurodegenerative disease? Neurology 2013;80:132-8.
21. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-81.
22. Brodaty H, Seeher K, Gibson L. Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr 2012;24:1034-45.
23. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996-2005. (Pubitemid 41253267)
24. Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 2012;26:841-70.
25. Vercelletto M, Boutoleau-Bretonnière C, Volteau C, Puel M, Auriacombe S, Sarazin M, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011;23:749-59.
26. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355-9. (Pubitemid 38721158)
27. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacol 2004;172:400-8. (Pubitemid 38650975)
28. Czarnecki K, Kumar N, Josephs KA. Parkinsonism and tardive antecollis in frontotemporal dementia -increased sensitivity to newer antipsychotics? Eur J Neurol 2008;15:199-201.
29. Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DG, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain 2011;134:2493-501.
30. Gass J, Prudencio M, Stetler C, Petrucelli L. Progranulin: an emerging target for FTLD therapies. Brain Res 2012;1462:118-28.
31. Rohrer JD, Frisoni GB, Galimberti D, Masellis M, Rowe JB, Borroni B, et al. GENFI -The GENetic Frontotemporal Dementia Initiative. Dement Geriatr Cogn Disord 2012;34(suppl 1):1-289.
32. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42-52.
33. Mahoney CJ, Malone IB, Ridgway GR, Buckley AH, Downey LE, Golden HL, et al. White matter tract signatures of the progressive aphasias. Neurobiol Aging 2013, doi:10.1016/j.neurobiolaging.2012.12.002. [epub ahead of print].
34. Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci (forthcoming).